Stayble Therapeutics AB

Stayble Therapeutics AB is a Sweden-based life science company developing an injectable treatment STA363 against chronic low back pain triggered by disc degeneration. The solutions are offered to the patients whose back pain persists after physiotherapy and drugs. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. Main focus of the Company is to develop STA363 as a new way of treatment for patients suffering from chronic disc-related low back pain. STA363 focuses on the two primary causes of pain in degenerative disc disease: leakage of inflammatory substances and disc instability. The mechanism of action of the treatment is to stabilize the disk segment and eliminate the possibility of disk leakage.